- are implementing year-on-year emissions reductions towards the 2015 Paris goal of limiting global warming to 1.5 degrees Celsius above pre-industrial levels, the report noted.
The analysis - which excluded the substantial carbon impact of government labs, universities, and healthcare systems - found that the total carbon impact of 231 publicly-listed biopharma companies increased 15% to 227 million metric tons of carbon dioxide equivalent in 2021 from 197 million in 2020.The measurement of carbon impact includes all three categories of emissions.
Reporting of scope 3 emissions remains imperfect, there is no standardisation on how this data is gathered and measured, said Connelly. Meanwhile, of the 75 publicly-traded companies with the best available data for the past six years, scope 1 and 2 emissions have increased, particularly over the past two years. More worryingly only 9% of this cohort have targets aligned with the 1.5˚C target.